Olive Garden's seven-item "Lighter Portions" menu rolled out nationwide in January. Chipotle added a protein-forward bowl designed for smaller appetites. Subway restructured its kids' menu for adult purchasers. The common thread: GLP-1 drugs like Ozempic and Wegovy have reduced the appetites of tens of millions of Americans, and the restaurant industry is adapting its business model to match [1].

NBC News reported in January that national chains are "quietly redesigning their menus" around the reality that a growing segment of their customer base simply cannot eat as much as they used to [2]. The changes are subtle — smaller default portions, higher protein-to-carbohydrate ratios, more nutrient-dense options labeled in language that avoids mentioning weight loss drugs directly. As one industry consultant told CNBC, the preferred terminology is "nutrient dense" or "high protein," never "Ozempic-friendly" [3].

The financial logic is straightforward. An estimated 15 million Americans are now on GLP-1 medications, a number projected to reach 30 million by 2028 [4]. These customers still eat out — they just eat less. A restaurant that serves them 40 percent less food at 80 percent of the old price improves margins while appearing responsive.

WBUR's Here and Now noted that the trend has expanded beyond GLP-1 users [5]. Smaller portions, once stigmatized as insufficient, are now positioned as desirable. The cultural shift is real: a generation raised on supersized meals is watching the default shrink. Whether this is a health revolution or a pricing strategy disguised as one depends on which side of the menu you're reading.

-- Nora Whitfield, Chicago